Ophthalmologic device and pharmaceutical developer Avedro has raised $25 million in Series C venture capital financing. The funding round was led by SCP Vitalife and Aperture Venture Partners.
Jeff Dykan of SCP Vitalife will join the Avedro board of directors, while Eric Sillman of Aperture Venture Partners will join as a board observer. The financing will help the company expand commercial operations of the Vedera and KXL Systems outside the U.S. and seek U.S. Food and Drug Administration clearance for the products.
Click here for the release from Business Wire.